A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.
Epistemonikos ID: b9621f15195fcbdc444d272ff317a7207f21e88a
First added on: May 15, 2024